VioQuest Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of clinical stage drug therapies for the treatment of oncology and infectious diseases. Its lead product includes Xyfid, which is under development for the treatment and prevention of hand-foot syndrome. The company's products also consist of VQD-002, a nucleoside analog that...
Its market capitalization was $163,849 as of August 4, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2007; market data as of August 4, 2026.
No profile data available.